Abstract
The approval of sipuleucel-T for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer (CRPC) has validated immunotherapy, in general, as a valid approach for this disease. Multiple novel immune based approaches including adenoviral-based vector delivering targeted antigen, DNAbased vaccination, listeria-based vaccination, pox-viral based approach, immune checkpoint blockade and radioimmunoconjugates appear promising. In concert with the development of new immunotherapeutics, the development of optimal intermediate endpoints for clinical efficacy, measures of an optimal immune response and biomarkers predictive for benefit are warranted. We briefly review emerging immunotherapeutic approaches to treat patients with CRPC.
Keywords: Immunotherapy, Castration resistant, Prostate cancer, Sipuleucel-T, Immunotherapy, Novel
Current Cancer Therapy Reviews
Title:Approaches Used in Immunotherapy for Prostate Cancer
Volume: 8 Issue: 4
Author(s): Guru Sonpavde
Affiliation:
Keywords: Immunotherapy, Castration resistant, Prostate cancer, Sipuleucel-T, Immunotherapy, Novel
Abstract: The approval of sipuleucel-T for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer (CRPC) has validated immunotherapy, in general, as a valid approach for this disease. Multiple novel immune based approaches including adenoviral-based vector delivering targeted antigen, DNAbased vaccination, listeria-based vaccination, pox-viral based approach, immune checkpoint blockade and radioimmunoconjugates appear promising. In concert with the development of new immunotherapeutics, the development of optimal intermediate endpoints for clinical efficacy, measures of an optimal immune response and biomarkers predictive for benefit are warranted. We briefly review emerging immunotherapeutic approaches to treat patients with CRPC.
Export Options
About this article
Cite this article as:
Sonpavde Guru, Approaches Used in Immunotherapy for Prostate Cancer, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040238
DOI https://dx.doi.org/10.2174/1573394711208040238 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intracellular Trafficking of MDR Transporters and Relevance of SNPs
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Classes of Sigma2 (σ2) Receptor Ligands: Structure Affinity Relationship (SAfiR) Studies and Antiproliferative Activity
Current Pharmaceutical Design Recent Advances in Peptide-Based Approaches for Cancer Treatment
Current Medicinal Chemistry In Silico Methods for Predicting Ligand Binding Determinants of Cytochromes P450
Current Topics in Medicinal Chemistry Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer
Reviews on Recent Clinical Trials Pharmacological Effect of Berberine Chloride in Propyl Thiouracil Induced Thyroidal Dysfunction - A Time Bound Study in Female Rats
Recent Patents on Drug Delivery & Formulation Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design Association of EGF rs4444903 and XPD rs13181 Polymorphisms with Cutaneous Melanoma in Caucasians
Medicinal Chemistry Known Triterpenes and their Derivatives as Scaffolds for the Development of New Therapeutic Agents for Cancer
Current Medicinal Chemistry Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Poly-Pharmacy Among the Elderly: Analyzing the Co-Morbidity of Hypertension and Diabetes
Current Pharmaceutical Design Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Microarray Technology as a Universal Tool for High-Throughput Analysis of Biological Systems
Combinatorial Chemistry & High Throughput Screening The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry